2026.10.08
On October 8, 2026, Hangzhou Detuo Biopharma (Detuo), a company specializing in discovering and developing molecular glue degraders (MGDs), announced its research collaboration and licensing agreement with Roche. The agreement is to jointly discover and develop novel MGDs targeting multiple points in oncology and immunology.
Detuo will collaborate with Roche and use its proprietary platform to discover MGDs for specific therapeutic targets. Once the project reaches designated research stages, Roche will take over the subsequent preclinical and clinical development and have the exclusive global commercialization rights.
Detuo's platform is a high-throughput degrader screening system that combines precision and efficiency. It is suitable for various types of target proteins including cytoplasmic, nuclear, transmembrane and viral proteins. Detuo has established degrader screening cell lines for over 100 clinical targets that cover therapeutic areas with traditionally ‘undruggable’ proteins. The company has also built a focused compound library targeting various E3 ligases to facilitate the discovery of novel MGDs.
JunHe was entrusted by Detuo Biopharma to review, amend and negotiate the agreement for this project. JunHe subsequently earned the trust and recognition of the company with our consistently efficient, rigorous work style and meticulous, dedicated service attitude.
The lead partner for this project was ZHAO, Hao (Gerry).